Welcome to our dedicated page for Optimi Health SEC filings (Ticker: OPTHF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Optimi Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Optimi Health's regulatory disclosures and financial reporting.
Optimi Health Corp. is registering 2,400,000 common shares in an initial public offering in the United States.
The prospectus also registers warrants to purchase up to 110,400 common shares (Underwriter Warrants) and up to 110,400 common shares issuable upon exercise of those Underwriter Warrants at a price equal to 120% of the IPO price. The IPO price is US$6.25 per share, with gross proceeds of US$15,000,000 before underwriting discounts. Proceeds to the issuer before expenses are shown as US$13,875,000. The underwriter has a 45-day option to purchase up to an additional 360,000 shares for over-allotments. Shares outstanding giving effect to the offering (assuming no over-allotment) are based on 3,225,899 common shares issued and outstanding as of the date of the prospectus.
Optimi Health Corp. is filing a preliminary prospectus for an initial public offering of 2,500,000 common shares and registration of up to 115,000 Underwriter Warrants (and 115,000 shares issuable on exercise). The prospectus states an expected price range of US$6.00 to US$8.00 per share and an underwriter overallotment option of 375,000 shares.
The company is a Canadian GMP-compliant manufacturer of MDMA and botanical psilocybin products with Health Canada licences (DEL, Dealer’s Licence, Precursor Licence), supplies prescription markets in Australia and access via Canada’s Special Access Program, and reports fiscal 2025 net loss of C$3,712,031 with an accumulated deficit of C$27,241,680 as of December 31, 2025. The board has approved a 1-for-30 Reverse Share Split intended to satisfy Nasdaq price requirements; Nasdaq listing is a condition to completing the offering.
Optimi Health Corp. is registering an initial public offering of 2,500,000 common shares in the United States. The prospectus states an expected initial public offering price range of US$6.00 to US$8.00 per share and registration of up to 143,750 Underwriter Warrants and up to 143,750 shares issuable upon exercise of those warrants.
The company has applied to list its common shares on Nasdaq under the symbol OPTH, and completion of the offering is conditioned on Nasdaq approval. The filing also discloses a Board‑approved 1‑for‑30 reverse share split to be effected immediately prior to effectiveness and states there were 3,225,899 common shares issued and outstanding as of the date of this prospectus (post‑split basis reflected). The company describes GMP‑certified manufacturing, current regulated supply in Australia and Canada, ongoing third‑party clinical trials in certain markets, and material regulatory, supply and financing risks in its risk factors.
Optimi Health Corp. filed Amendment No. 6 to its Form F-1 registration statement, submitting an amended Filing Fee Table as Exhibit 107 and updating the Exhibit Index and signature pages. The amendment is exhibit-only; the prospectus and the remainder of Part II are unchanged.
Optimi Health Corp. filed an amended Form F-1 registration statement to list on Nasdaq and raise capital through an initial public offering of 2,500,000 common shares. The offering includes warrants to purchase up to 143,750 common shares and an underwriter option of 375,000 shares to cover over-allotments. The expected initial public offering price range is US$6.00 to US$8.00 per share. The company applied to list its common shares on the Nasdaq Capital Market under the symbol OPTH and plans a 1-for-30 reverse share split immediately prior to effectiveness to meet Nasdaq minimum price requirements. The prospectus notes the company is a Canadian GMP-compliant manufacturer of MDMA and botanical psilocybin products, currently supplying prescription markets in Australia and access in Canada through the Special Access Program, while U.S. commercialization requires regulatory rescheduling. Financial summaries show recent losses and a December 31, 2025 consolidated cash/asset picture with total assets of C$14.24M and shareholders' equity of C$5.02M.
Optimi Health Corp. is conducting an initial public offering of 2,500,000 Units, each Unit consisting of one common share and one warrant. The Units are expected to price between US$6.00 and US$8.00 per Unit. The prospectus registers up to 2,875,000 common shares issuable upon exercise of the Common Warrants (including the underwriter over-allotment assumption) and up to 143,750 Underwriter Warrants and the 143,750 common shares issuable upon their exercise. The Common Warrants are exercisable at an assumed exercise price equal to 120% of the initial public offering price per Unit and expire two years from issuance; the Underwriter Warrants have the same 120% exercise price construct. The offering contemplates a 1-for-30 Reverse Share Split to be effected immediately prior to effectiveness to meet Nasdaq minimum share price requirements. The number of common shares outstanding used in the prospectus pro forma is 3,225,899 as of the date of the prospectus.
Optimi Health Corp. is conducting an initial public offering of 2,500,000 common shares in the United States, and is registering related underwriter warrants to purchase up to 143,750 common shares plus the shares issuable on their exercise. The prospectus assumes an initial public offering price between US$6.00 and US$8.00 per share and reflects an approved 1-for-30 reverse share split to meet Nasdaq listing requirements. The company has applied to list on Nasdaq under the symbol OPTH and currently trades on the CSE (OPTI), FSE (8BN) and OTCQX (OPTHF). Financials show revenue and recurring losses, with a December 31, 2025 cash/asset snapshot and accumulated deficit disclosed; the company states existing cash, term loan funding and this offering are expected to fund operations for the next 12 months.
Optimi Health Corp. is registering an initial public offering in the United States of 2,142,857 common shares.
The registration also covers underwriting arrangements including warrants to purchase up to 123,214 common shares and an equal number of shares issuable upon exercise of those warrants. The prospectus assumes an initial public offering price between US$6.00 and US$8.00 per share. Completion of the offering is conditioned on approval for listing on the Nasdaq Capital Market. The company has approved a 1-for-30 reverse share split to be effected prior to effectiveness; all share data in the prospectus reflect that split.